NY-ESO-1 TCR-engineered T cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for NY-ESO-1 TCR-engineered T cells, covering 2024-09-19 to 2024-09-19. Get the full timeline:
Most recent: Clinical Trial Update: Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1]